Regulatory approval

Published by the Health Canada. Approved

KADCYLA monotherapy indicated for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.

This is written in the approval document.

Citation

Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals